SVRA — Savara Inc.

Savara (SVRA) Q2 2020 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: $9.4 million for Q2 2020 ($0.16 per share), down from $21.9 million ($0.57 per share) in Q2 2019.
• Research and Development Expenses: Decreased by 42% to $6.1 million, attributed to lower study costs and wrapping up enrollment for ongoing studies.
• General and Administrative Expenses: Decreased by 26% to $3.1 million, primarily due to reduced commercial activities.
• Cash Position: As of June 30, 2020, cash, cash equivalents, and short-term investments totaled approximately $100 million, with $25 million in debt. The company expects sufficient capital to fund operations through the anticipated second tranche of financing.

2. Strategic Updates and Business Highlights

• IMPALA 2 Study: The design for the Phase III IMPALA 2 clinical study has been finalized, with plans to start in Q1 2021. The study will involve 160 patients and will assess efficacy through a double-blind, placebo-controlled format.
• COVID-19 Adaptations: The company is implementing measures to mitigate COVID-19 disruptions, including telemedicine visits and maintaining drug supply for ongoing studies.
• AVAIL and ENCORE Studies: Enrollment in the AVAIL study reached 133 patients (target 150), while the ENCORE study is 50% enrolled with 14 patients (target 50). Both studies faced challenges due to COVID-19 but continued with enrolled patients.

3. Forward Guidance and Outlook

• Top-Line Results: Expected for the AVAIL study in early 2021.
• Regulatory Discussions: The company aims to engage with the FDA regarding the aPAP program as soon as feasible, potentially this year or early next year.
• Operational Plans: Savara is confident in executing its strategy, particularly with three Phase III programs underway.

4. Bad News, Challenges, or Points of Concern

• Enrollment Challenges: The AVAIL study's enrollment was below expectations, which may impact statistical power and outcomes.
• Competitive Pressures: The emergence of Trikafta, a CFTR modulator, could affect the market for AeroVanc, as the AVAIL study does not assess its combination with AeroVanc.
• COVID-19 Impact: Although proactive measures are in place, the ongoing pandemic presents uncertainty regarding study timelines and patient enrollment.

5. Notable Q&A Insights

• Study Site Distribution: Approximately 20 sites will open in the U.S. and Canada, with additional sites across 8-9 countries in the EU and Japan/Korea.
• FDA Submission Timing: The FDA will likely require 48-week data for any application submission, aligning with the study's design.
• Whole Lung Lavage Impact: Concerns were raised about the impact of whole lung lavage on study outcomes, with the company acknowledging that while it may improve gas transfer, its effect on DLCO remains uncertain.

Overall, Savara is making progress with its clinical studies and maintaining a strong financial position, but it faces challenges related to enrollment and competitive pressures in the market.